المؤلفون: Hongxing Shen, Fengyuan Huang, Xiangmin Zhang, Oluwagbemiga A. Ojo, Yuebin Li, Hoa Quang Trummell, Joshua C. Anderson, John Fiveash, Markus Bredel, Eddy S. Yang, Christopher D. Willey, Zechen Chong, James A. Bonner, Lewis Zhichang Shi

المصدر: Nature Communications, Vol 13, Iss 1, Pp 1-17 (2022)

مصطلحات موضوعية: Science

وصف الملف: electronic resource

Relation: https://doaj.org/toc/2041-1723

URL الوصول: https://doaj.org/article/d38ce33d0e5a4670b226973e3a573576

المؤلفون: Andra V. Krauze, Albert Attia, Steve Braunstein, Michael Chan, Stephanie E. Combs, Rainer Fietkau, John Fiveash, John Flickinger, Anca Grosu, Steven Howard, Carsten Nieder, Maximilian Niyazi, Lindsay Rowe, Dee Dee Smart, Christina Tsien, Kevin Camphausen

المصدر: Radiation Oncology, Vol 12, Iss 1, Pp 1-10 (2017)

مصطلحات موضوعية: Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: http://link.springer.com/article/10.1186/s13014-017-0928-3; https://doaj.org/toc/1748-717X

URL الوصول: https://doaj.org/article/0817cf9a55514927950c9abd508eae69

المؤلفون: Hassan M Fathallah-Shaykh, Andrew DeAtkine, Elizabeth Coffee, Elias Khayat, Asim K Bag, Xiaosi Han, Paula Province Warren, Markus Bredel, John Fiveash, James Markert, Nidhal Bouaynaya, Louis B Nabors

المصدر: PLoS Medicine, Vol 16, Iss 5, p e1002810 (2019)

مصطلحات موضوعية: Medicine

وصف الملف: electronic resource

Relation: https://doaj.org/toc/1549-1277; https://doaj.org/toc/1549-1676

URL الوصول: https://doaj.org/article/e441b3800dc947889c741a43b9a773a6

المؤلفون: Andra V. Krauze, Albert Attia, Steve Braunstein, Michael Chan, Stephanie E. Combs, Rainer Fietkau, John Fiveash, John Flickinger, Anca Grosu, Steven Howard, Carsten Nieder, Maximilian Niyazi, Lindsay Rowe, Dee Dee Smart, Christina Tsien, Kevin Camphausen

المصدر: Radiation Oncology, Vol 13, Iss 1, Pp 1-1 (2018)

مصطلحات موضوعية: Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: http://link.springer.com/article/10.1186/s13014-018-0955-8; https://doaj.org/toc/1748-717X

URL الوصول: https://doaj.org/article/ba94e8ad4bf14c70ac702283d0ad54ab

المؤلفون: Martin R. Johnson, L. Burt Nabors, Hassan M. Fathallah-Shaykh, Alan Cantor, Cheryl A. Palmer, John Fiveash, Jessica M. Grunda

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03c11747eddac034c592e700e1814044
https://doi.org/10.1158/1078-0432.22442523

المؤلفون: Martin R. Johnson, L. Burt Nabors, Hassan M. Fathallah-Shaykh, Alan Cantor, Cheryl A. Palmer, John Fiveash, Jessica M. Grunda

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6855070a92325032c848437a2543ca1f
https://doi.org/10.1158/1078-0432.c.6519237.v1

المؤلفون: Christopher Collette, Gabrielle Willhelm, Victor A. Del Bene, Stephen L. Aita, Dario Marotta, Terina Myers, Joseph Anderson, Meredith Gammon, Adam Gerstenecker, L. Burt Nabors, John Fiveash, Kristen L. Triebel

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::ddac05f463ca1403b26c97a21dbe6ad8
https://doi.org/10.1101/2022.11.10.22282138

المؤلفون: James Mooney, Arsalaan Salehani, Nicholas Erickson, Evan Thomas, Adeel Ilyas, Sage Rahm, Nicholas Eustace, Pedram Maleknia, Omer Yousuf, Markus Bredel, John Fiveash, Chris Dobelbower, Winfield Fisher

المصدر: Surgical neurology international. 13

مصطلحات موضوعية: Surgery, Neurology (clinical)

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82f2f23c3eed7a8d4c1486f3ab08d35a
https://pubmed.ncbi.nlm.nih.gov/35673645

المؤلفون: Nicholas Erickson, James Mooney, Arsalaan Salehani, Evan Thomas, Adeel Ilyas, Sage Rahm, Pedram Maleknia, Omer Yousuf, John Fiveash, Chris Dobelbower, Winfield S. Fisher

المصدر: World neurosurgery. 160

مصطلحات موضوعية: Intracranial Arteriovenous Malformations, Treatment Outcome, Humans, Surgery, Neurology (clinical), Radiosurgery, Embolization, Therapeutic, Follow-Up Studies, Retrospective Studies

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e14fcc51fb8f9b8072c2f6a640abdcce
https://pubmed.ncbi.nlm.nih.gov/35077887

المؤلفون: Alicia M Waters, James M Johnston, Alyssa T Reddy, John Fiveash, Avi Madan-Swain, Kara Kachurak, Asim K Bag, G. Yancey Gillespie, James M Markert, Gregory K Friedman

المصدر: Human Gene Therapy Clinical Development.

مصطلحات موضوعية: 0301 basic medicine, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, 030220 oncology & carcinogenesis, Genetics (clinical)

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::508ab3ecea3bd376b1d4997061574fc8
https://doi.org/10.1089/hum.2017.002

المؤلفون: David C, Hockaday, Sui, Shen, John, Fiveash, Andrew, Raubitschek, David, Colcher, An, Liu, Vern, Alvarez, Adam N, Mamelak

المصدر: Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 46(4)

مصطلحات موضوعية: Adult, Male, Brain Neoplasms, Metabolic Clearance Rate, Brain, Reproducibility of Results, Scorpion Venoms, Glioma, Sensitivity and Specificity, Organ Specificity, Feasibility Studies, Humans, Female, Tissue Distribution, Radiopharmaceuticals, Radionuclide Imaging

URL الوصول: https://explore.openaire.eu/search/publication?articleId=pmid________::6bc01cdf73ed4f3a7d4ebb28e25f3d65
https://pubmed.ncbi.nlm.nih.gov/15809479

المساهمون: John Fiveash, MD, Assistant Professor - Department of Radiation Oncology

المصدر: A Phase I Dose Escalation Trial of Five Fraction Stereotactic Radiation Therapy for Brain

المساهمون: John Fiveash, MD, Principal Investigator

المصدر: RAD 1601: Pilot Trial of Frameless Virtual Cone Stereotactic Radiosurgical Thalamotomy for Intractable Tremor and Advanced Functional Connectivity Parcellation of the Thalamus

المساهمون: John Fiveash, MD, Principal Investigator

المصدر: RAD 1501: A Phase II Trial of Virtual Cone Trigeminal Neuralgia Radiosurgery

المؤلفون: Integrated Therapeutics Group

المساهمون: John Fiveash, MD, Professor and Vice Chair, University of Alabama at Birmingham Department of Radiation Oncology

المصدر: Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases
DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology. 1989 Jun;39(6):789-96. doi: 10.1212/wnl.39.6.789.
Pirzkall A, Debus J, Lohr F, Fuss M, Rhein B, Engenhart-Cabillic R, Wannenmacher M. Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. J Clin Oncol. 1998 Nov;16(11):3563-9. doi: 10.1200/JCO.1998.16.11.3563.
Sneed PK, Lamborn KR, Forstner JM, McDermott MW, Chang S, Park E, Gutin PH, Phillips TL, Wara WM, Larson DA. Radiosurgery for brain metastases: is whole brain radiotherapy necessary? Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):549-58. doi: 10.1016/s0360-3016(98)00447-7.
Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA, Young B. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998 Nov 4;280(17):1485-9. doi: 10.1001/jama.280.17.1485.
Stevens MF, Hickman JA, Stone R, Gibson NW, Baig GU, Lunt E, Newton CG. Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent. J Med Chem. 1984 Feb;27(2):196-201. doi: 10.1021/jm00368a016.
Tsang LL, Quarterman CP, Gescher A, Slack JA. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide. Cancer Chemother Pharmacol. 1991;27(5):342-6. doi: 10.1007/BF00688855.
Bull VL, Tisdale MJ. Antitumour imidazotetrazines--XVI. Macromolecular alkylation by 3-substituted imidazotetrazinones. Biochem Pharmacol. 1987 Oct 1;36(19):3215-20. doi: 10.1016/0006-2952(87)90636-8.
Tisdale MJ. Antitumour imidazotetrazines--XVIII. Modification of the level of 5-methylcytosine in DNA by 3-substituted imidazotetrazinones. Biochem Pharmacol. 1989 Apr 1;38(7):1097-101. doi: 10.1016/0006-2952(89)90254-2.
Tsang LL, Farmer PB, Gescher A, Slack JA. Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity. Cancer Chemother Pharmacol. 1990;26(6):429-36. doi: 10.1007/BF02994094.
Clark AS, Stevens MF, Sansom CE, Schwalbe CH. Anti-tumour imidazotetrazines. Part XXI. Mitozolomide and temozolomide: probes for the major groove of DNA. Anticancer Drug Des. 1990 Feb;5(1):63-8.
Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW, Slack JA, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 1987 Nov 15;47(22):5846-52.
Gibson NW, Hickman JA, Erickson LC. DNA cross-linking and cytotoxicity in normal and transformed human cells treated in vitro with 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d] -1,2,3,5-tetrazin-4(3H)-one. Cancer Res. 1984 May;44(5):1772-5.
Hartley JA, Gibson NW, Kohn KW, Mattes WB. DNA sequence selectivity of guanine-N7 alkylation by three antitumor chloroethylating agents. Cancer Res. 1986 Apr;46(4 Pt 2):1943-7.
SN92384: SCH 52365: Pharmacokinetics of SCH 52365 in Rats Following a Single Oral Gavage or Intravenous Dose. Schering-Plough Research Institute
SN92385: SCH 52365: Pharmacokinetics of SCH 52365 in Beagle Dogs Following a Single Oral Gavage or a Single Intravenous Cross-Over Study. Schering Plough Research Institute
SN92131: Single-Cycle Oral Toxicity Study of SCH 52365 in Rats. Schering Plough Research Institute.
SN93092: Single-Cycle Oral Toxicity Study with Lower Doses of SCH 52365 in Rats. Schering-Plough Research Institute
SN92133: Three-Cycle Oral Toxicity Study of SCH 52365 in Rats. Schering Plough Research Institute.
SN92132: Single-Cycle Oral Toxicity Study of SCH 52365 in Dogs. Schering-Plough Research Institute
SN93093: Single-Cycle Oral Toxicity Study with Lower Doses of SCH 52365 in Dogs. Schering-Plough Research Institute
SN92134: Three-Cycle Oral Toxicity Study of SCH 52365 in Dogs. Schering-Plough Research Institute
SN92380: SCH 52365: Mass Balance and Excretion of 14C-SCH 52365 Following a Single Intravenous or Oral Dose in Male Rats. Schering-Plough Research Institute
SN92383: SCH 52365: Absorption, Distribution and Metabolism of 14C SCH 52365 Following a Single Oral Dose in Male Rats. Schering-Plough Research Institute
SN92381: SCH 52365: Absorption, Metabolism, Excretion, and Pharmacokinetics of 14C-SCH 52365 Following a Single Oral or Intravenous Dose in the Male Rat. Schering-Plough Research Institute
SN92382: SCH 52365: Absorption, Metabolism, Excretion, and Pharmacokinetics of 14C-SCH 52365 Following a Single Oral And Intravenous Dose in the Male Dog. Schering-Plough Research Institute
Patel M, McCully C, Godwin K, Balis FM. Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol. 2003 Feb;61(3):203-7. doi: 10.1023/a:1022592913323.
Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, Quarterman CP, Hoffman R, Stevens MF, Brampton MH, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer. 1992 Feb;65(2):287-91. doi: 10.1038/bjc.1992.57.
O'Reilly SM, Newlands ES, Stevens MFG, Brampton MH, Slack JA et al: Temozolomide (CCRG 81045; M&B 39831; NSC 362856): a new oral cytotoxic agent with activity against melanoma, mycosis fungoides and high-grade glioma. Proc. AACR. 1992; 33: A1267
O'Reilly SM, Newlands ES, Glaser MG, Brampton M, Rice-Edwards JM, Illingworth RD, Richards PG, Kennard C, Colquhoun IR, Lewis P, et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer. 1993;29A(7):940-2. doi: 10.1016/s0959-8049(05)80198-4. Erratum In: Eur J Cancer 1993;29A(10):1500.
Data on file at the Cancer Research Campaign Data Center. Phase II trial of temozolomide in high-grade glioma. Schering-Plough Research Institute. Study No. H93-090-50).
Data on file at the Cancer Research Campaign Data Center. Phase II trial of temozolomide in advanced malignant melanoma. Schering-Plough Research Institute. Study No. H93 088-50
Bleehen NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, Rustin GJ, Brampton M, Stevens MF. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol. 1995 Apr;13(4):910-3. doi: 10.1200/JCO.1995.13.4.910.
Data on file at the Cancer Research Campaign Data Center. Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma. Schering-Plough Research Institute. Study No. H93-089-50).
Woll PJ, Crowther D, Johnson PW, Soukop M, Harper PG, Harris M, Brampton MH, Newlands ES. Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma. Br J Cancer. 1995 Jul;72(1):183-4. doi: 10.1038/bjc.1995.299.
Data on file at Schering-Plough Research Institute (I93-114-01).
Brada M, Moore S, Judson I, Batra VJ, Quartey P, Dugan M: A Phase I study of SCH 52365 (temozolomide) in adult patients with advanced cancer. Proc. ASCO. 1995; 14:1521
Data on file at Schering-Plough Research Institute (C94-022-01).
Hammond LA, Eckardt JR, Baker SD, Eckhardt SG, Dugan M, Forral K, Reidenberg P, Statkevich P, Weiss GR, Rinaldi DA, Von Hoff DD, Rowinsky EK. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol. 1999 Aug;17(8):2604-13. doi: 10.1200/JCO.1999.17.8.2604.
Yung A, Levin VA, Albright R, Olson J, Fredericks R, Fink K, Prados M, Brada M, Spence A, Brunner J, Yue N, Dugan MH, Zaknoen S. Temodal Brain Tumor Group: Randomized trial of temodal (TEM) vs. procarbazine (PCB) in glioblastoma multi-forme (GBM) at first relapse [abstract]. Proceedings of the American Society of Clinical Oncology. 1999; 18:139a.
Christodoulou C, Bafaloukos D, Kosmidis P, Samantas E, Bamias A, Papakostas P, Karabelis A, Bacoyiannis C, Skarlos DV; Hellenic Cooperative Oncology Group. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol. 2001 Feb;12(2):249-54. doi: 10.1023/a:1008354323167.
Paraskevaidis E, Antonadou D, Sarris G, Kolliarakis N, Economou I, Karageirgus P, Throuvalas N. A Phase II randomized trial of synchronous radiotherapy with temozolomide in brain metastases. Metaxas Cancer Hospital, Pireus, Greece
Abrey JD, Olson DY, Boutros M, Mack A, Rodavitch JJ, Raizer MG. A Phase II Study of Temozolomide for Recurrent Brain Metastases. Malkin; Memorial Sloan-Kettering Cancer Center, New York, NY. Abstract 643

المساهمون: John Fiveash, MD, Professor and Vice Chair, University of Alabama at Birmingham Department of Radiation Oncology

المصدر: RAD 1203: Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer

المساهمون: John Fiveash, MD, Professor and Vice Chair, University of Alabama at Birmingham Department of Radiation Oncology

المصدر: RAD 1002: Phase I Dose Escalation/De-escalation Study of Pre-operative Stereotactic Radiosurgery for Brain Metastases

المؤلفون: Health Services Foundation, The Kirklin Clinic at Acton Road

المساهمون: John Fiveash, MD, Professor and Vice Chair, University of Alabama at Birmingham Department of Radiation Oncology

المصدر: A Phase II Study of Spinal Radiosurgery
Abbatucci JS, Delozier T, Quint R, Roussel A, Brune D. Radiation myelopathy of the cervical spinal cord: time, dose and volume factors. Int J Radiat Oncol Biol Phys. 1978 Mar-Apr;4(3-4):239-48. doi: 10.1016/0360-3016(78)90144-x. No abstract available.
Ang KK, Jiang GL, Feng Y, Stephens LC, Tucker SL, Price RE. Extent and kinetics of recovery of occult spinal cord injury. Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):1013-20. doi: 10.1016/s0360-3016(01)01599-1.
Bilsky MH, Yamada Y, Yenice KM, Lovelock M, Hunt M, Gutin PH, Leibel SA. Intensity-modulated stereotactic radiotherapy of paraspinal tumors: a preliminary report. Neurosurgery. 2004 Apr;54(4):823-30; discussion 830-1. doi: 10.1227/01.neu.0000114263.01917.1e.
Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain. 1983 Oct;17(2):197-210. doi: 10.1016/0304-3959(83)90143-4.
Delattre JY, Rosenblum MK, Thaler HT, Mandell L, Shapiro WR, Posner JB. A model of radiation myelopathy in the rat. Pathology, regional capillary permeability changes and treatment with dexamethasone. Brain. 1988 Dec;111 ( Pt 6):1319-36. doi: 10.1093/brain/111.6.1319.
Gerszten PC, Ozhasoglu C, Burton SA, Vogel WJ, Atkins BA, Kalnicki S, Welch WC. CyberKnife frameless stereotactic radiosurgery for spinal lesions: clinical experience in 125 cases. Neurosurgery. 2004 Jul;55(1):89-98; discussion 98-9.
Glanzmann C, Aberle HG, Horst W. The risk of chronic progressive radiation myelopathy. Strahlentherapie. 1976 Oct;152(4):363-72.
Nieder C: Recommendation of Human Spinal Cord Re-irradiation Dose Based on Data From 39 Patients. Int J Radiat Oncol Biol Phys 57:373, 2003
Schultheiss TE, Stephens LC. Invited review: permanent radiation myelopathy. Br J Radiol. 1992 Sep;65(777):737-53. doi: 10.1259/0007-1285-65-777-737. No abstract available.
Schultheiss TE, Stephens LC, Jiang GL, Ang KK, Peters LJ. Radiation myelopathy in primates treated with conventional fractionation. Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):935-40. doi: 10.1016/0360-3016(90)90015-c.
Schultheiss TE, Stephens LC, Maor MH. Analysis of the histopathology of radiation myelopathy. Int J Radiat Oncol Biol Phys. 1988 Jan;14(1):27-32. doi: 10.1016/0360-3016(88)90046-6.